 Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC non-squamous histology; squamous histology, CRC, pancreatic cancer, ovarian cancer, and sarcoma. 